Consolidated Statements of Operations (Unaudited) - USD ($) $ / shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Expenses:
Research and development	132,724	1,577
Selling, general and administrative	83,406	71,788
Stock-based compensation (Note 7)	177,490
Total expenses	393,620	73,365
Loss from operations	(393,620)	(73,365)
Other income
Interest income		96
Nonoperating Income (Expense), Total		96
Net loss	$ (393,620)	$ (73,269)
Net loss per share - basic and diluted (in dollars per share)	$ 0	$ 0
Weighted average number of common shares outstanding – basic and diluted (in shares)	86,522,569	67,022,568